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The pharmacokinetic parameters of D-penicillamine were investigated by administering four 
intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female 
mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg in man. The pharma- 
c, okinetics of D-penicillamine demonstrated nonlinearity in the dog. There was more than 
proportional increase in the area under the whole blood concentration curve for an increase in 
the bolus intravenous dose. The steady state whole blood, plasma, and packed cell levels of 
penicillamine were increased more than proportionately for an increase in the intravenous infusion 
rate. Total body clearance of penicillamine was decreased by increasing the dose or the infusion 
rate of peniciIlamine. Correspondingly, the estimated half-life of unchanged penicillamine in 
the whole blood was decreased for increased intravenous bolus doses. The renal clearance of 
peniciIlamine was nonlinear, decreasing with time during the bolus experiments and increasing 
at higher infusion rates. The nonrenal clearance was decreased at higher infusion rates, suggesting 
that a saturable nonrenal elimination process exists for penicillamine in the dog. The nonlinearities 
that were observed in the dog, if also present in man, may be responsible in part for tile dose 
related side effects reported clinically for peniciUamine. 
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INTRODUCTION 
Penicillamine has been used therapeutically since 1954 when Walshe 
first introduced the agent for the treatment of Wilson's disease (1). The 
name, penicillamine, was coined by Abrams et al. (2) when the amino acid 
was first isolated as a degradation product of penicillin. More recent studies 
of its therapeutic activities (3,4) have shown penicillamine to be effective 
in the treatment of rheumatoid arthritis. 
The latter application has prompted a greater usage of this drug and 
concomitantly an increased interest in research on it. A major stimulus for 
this increased usage and research is the high incidence and debilitating 
nature of rheumatoid arthritis. However, throughout the several decades 
of penicillamine therapy, pharmacokinetic studies have never been 
adequately carried out, primarily due to the lack of a specific and sensitive 
assay for the compound. Due to penicillamine's chemical similarity to a 
number of endogenous compounds, a specific assay is essential to accurately 
define its pharmacokinetics. Many very sensitive analytical methodologies 
which have been developed for penicillamine, such as colorimetric (5), gas 
chromatographic (6), and radioimmunoassay (7,8), are not useful for 
pharmacokinetic studies as a result of the possibility of interference from 
endogeneous compounds or penicillamine's metabolites or as a result of 
other limitations of these analytical methodologies. 
To avoid these analytical assay problems, previous penicillamine phar- 
macokinetic studies have been done in animals (9-14) and man (15-17) 
using radiolabeled penicillamine. These studies are inappropriate to 
describe pharmacokinetics of unchanged penicillamine, however, as the 
results represent both the parent compound, penicillamine, and penicil- 
lamine's metabolites or metabonates: penicillamine disulfide, penicillamine 
cysteine disulfide, and S-methyl-penicillamine (18). 
To further complicate the study of penicillamine pharmacokinetics, in 
vitro studies in our laboratory have shown a rapid loss of penicillamine in 
whole blood, plasma, and albumin solutions (19). Thus to accurately reflect 
the concentration of the unchanged drug in biological samples, the analytical 
samples must be processed quickly to avoid a significant change in the 
penicillamine concentration. The studies reported in this paper used 
methods reported previously (19) to stabilize the reduced penicillamine 
present in the samples. 
The recent development of a high performance liquid chromatographic 
(HPLC) method for the determination of penicillamine (20,21) has provided 
an assay method with the specificity and sensitivity necessary to conduct 
pharmacokinetic studies of unchanged penicillamine. We have modified 
this HPLC method and adapted it for use in our laboratory (22). In this 
paper, we present the results of intravenous bolus, intravenous infusion, 
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and oral administration pharmacokinetic studies of penicillamine in a 
female mongrel dog. 
E X P E R I M E N T A L  
Materials and Methods  
The pharmacokinetics of penicillamine were studied following the 
administration of single doses of penicillamine in a female mongrel dog 
(Hodgins Kennel, Howell, Mich. 48843). All of these studies were per- 
formed in a single dog to eliminate variation between animals. During the 
course of these studies, the dog's weight ranged from 21 to 28 kg. The 
doses of penicillamine were administered on a mg/kg basis to make the 
doses equivalent to 250, 500, 750, and 1000 mg of penicillamine in a 70 kg 
man. The dog's weight was accurately determined prior to each dose. 
For all studies, the dog was fasted for 24 hr prior to the dose and during 
the experimental period. The dog was conscious throughout the entire 
experimental procedure, and no anesthetic agents or tranquilizing drugs 
were administered at any time. The dog was restrained by means of a 
headlock sling apparatus. 
An indwelling foley urinary cannula inserted prior to each study was 
used to collect the urine specimens. An intravenous cannula (8 in., 19 
gauge), placed into the cephalic vein of the forepaw, was used to collect 
blood samples. From 2 to 3 ml of whole blood was withdrawn from the 
cannula and discarded prior to obtaining the actual 3-5 ml blood sample 
for analysis. On occasion, the cannula was flushed with sterile 0.9% sodium 
chloride between samples. Approximately 500ml of water was given 
through a gastric tube 30 min prior to the iv bolus and oral doses to promote 
adequate urine flow throughout the experimental period. During the 
infusion studies, 100 ml of water was given through a gastric tube at the 
start of each new infusion. 
The dosage form for all of these studies except the one dose 
administered in capsule form was an extemporaneously compounded sol- 
ution of penicillamine. The solution of penicillamine (50 mg/mt) was pre- 
pared in advance of all studies by dissolving D-peniciUamine (99% + purity, 
Aldrich Chemical Co., Milwaukee, Wis. 53233) in an ethylene diamine 
tetracetic acid disodium salt (EDTA) solution (1 g/liter). The solution was 
sterile filtered (25 mm 0.22 tzm membrane filter, Millipore Corp., Bedford, 
Mass. 01730) and was aseptically transferred into sterile 5 ml glass seal 
ampuls purged with sterile filtered nitrogen. The ampuls were aseptically 
sealed and then refrigerated until used. Ampuls of penicillamine prepared 
as above are reported to be stable for over a year (20,23). Assays of the 
penicillamine solution at the beginning and end of the studies confirmed 
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that no significant change of penicillamine concentration had occurred 
during storage. The one dose administered as capsules utilized 125 mg 
Cuprimine capsules (125 mg lot no. A1661, penicillamine, Merck Sharp 
and Dohme, West Point, Pa. 19486). 
Intravenous Bolus Administration 
Four doses of penicillamine (14.3, 10.7, 7.1, and 3.6 mg/kg) were 
administered by bolus intravenous injection (<5 s) via an intravenous 
cannula (8 in., 19 gauge) inserted in the opposite cephalic vein to that used 
for the blood sample site. The dosage administration cannula was immedi- 
ately flushed with 5 to 10 ml of sterile 0.9% sodium chloride solution 
following the dose. A single intravenous bolus dose was administered at 
intervals of 2 weeks to allow sufficient time for blood volume recovery and 
drug washout. Blank urine and whole blood samples were obtained prior 
to the start of every dose of penicillamine. Then whole blood samples were 
obtained at 1, 10, 20, 30, 40, 60, 80, 100, 120, 150, 180, 210, 240, 270, 
and 300 min after the dose. Total void urine samples were obtained at 0, 
15, 30, 45, 60, 90, 120, 180, 240, and 300 min. For all urine samples, the 
volume was accurately measured and recorded. 
Oral Administration 
Three doses of penicillamine (one 14.3 and two 10.7 mg/kg) were 
administered orally in solution form via a gastric tube. From 50 to 75 ml 
of water was administered immediately after the dose to flush the gastric 
tube. Blank whole blood and urine samples were collected prior to the 
dose. Then whole blood samples were obtained at 10, 20, 30, 40, 50, 60, 
70, 80, 90, 100, 120, 140, 160, 180, 210, 240, 270, 300, 330, and 360 rain 
after the administration of the dose of penicillamine. Urine samples were 
collected on a schedule similar to that of the I.V. bolus experiments. A 
similar oral administration experiment was also completed using a capsule 
dosage form. Two capsules (2 x 125 mg = 250 mg = 9.9 mg/kg) were 
administered orally, and blood and urine samples were obtained as detailed 
above. 
Intravenous Infusion Administration 
A total of six constant rate infusions (0.21, 0.41, 0.82, 1.3, 1.7, and 
2.1 mg/min) were administered on two separate days, two weeks apart, 
giving three consecutive increasing rate infusions on each day. The infusion 
rates (mass/time) were controlled by altering the concentration of the 
infusion solution (mg/ml) and maintaining a constant volume infusion rate 
(ml/min). For this purpose, a calibrated Harvard infusion pump (model 
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975, Harvard Apparatus, Millis, Mass. 02054) was used to maintain a 
constant volume infusion rate of 0.139 ml/min. Six solutions of penicil- 
lamine (1.5, 3.0, 6.0, 9.0, 12.0, and 15.0 mg/ml) in EDTA (1 g/liter) were 
infused through a sterile 25 mm 0.22 tzm membrane filter (Millipore Corp., 
Bedford, Mass. 01730) via an intravenous cannula inserted into the cephalic 
vein opposite to the site of the blood sample cannula. The concentrations 
of each of the infusion solutions were checked at the time of the assay of 
the pharmacokinetic samples to confirm their concentration. 
Each penicillamine solution was infused over a period of 4 hr to achieve 
a different steady state blood level of penicillamine. Blood samples, includ- 
ing whole blood, plasma, and packed cell fractions, were collected at three 
time points approximately 20 min apart during the fourth hour of each 
infusion. Urine formed during the first 3 hr of each infusion was collected 
and discarded. Then the urine excreted during the final fourth hour was 
collected over an accurately timed interval. The measurement of penicil- 
lamine in these urine samples allowed an accurate calculation of the renal 
clearance when the blood levels of penicillamine were at steady state. 
Sample Treatment and Assay Procedure 
The samples of whole blood, plasma, packed cells, or urine were 
treated immediately after collection to stabilize the amount of penicillamine 
present in the samples. The whole blood samples for the i.v. bolus and 
oral solution studies were drawn using plain 3 ml syringes. The blood 
samples for the i.v. infusion studies and oral capsule study were drawn 
using heparinized 5 ml syringes (approximately 50/~1 of 1000 U/ml heparin 
per 5 ml syringe). A rapid separation of blood into plasma and packed cell 
components was achieved using a high speed micro centrifuge (model 5412, 
Brinkmann Instrument Co., Westbury, N.Y. 11590) (15,000g for 30 s). 
Whole blood and packed cell samples were diluted (1:1) and hemolyzed 
using an EDTA solution (1 g/liter), and then the proteins were precipitated 
and the pH decreased by the addition of a metaphosphoric acid solution 
(500 g/liter) using 0.5 ml metaphosphoric acid solution per ml of whole 
blood or packed cells. The plasma samples were stabilized by the addition 
of 0.2 ml of a trichloroacetic acid solution (20% w/v) per ml of plasma, 
which caused a decrease in the pH and a precipitation of the plasmg 
proteins. These precipitates were centrifuged, and the supernatantg were 
decanted and immediately refrigerated or placed on ice. 
The urine samples were accurately measured for totai volume. Then 
( ~  P 9 9 
a suitable aliquot was diluted (1 : 5 or 1 : 10) using a ~.,+ M citric acid solution 
to decrease the pH and stabilize the penicillamine. The protein free super- 
natants from whole blood, plasma, and packed cells and the diluted urine 
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samples were assayed for penicillamine using our modification (22) of the 
previously published electrochemical HPLC assay (20) for penicillamine. 
RESULTS 
l . V .  Bolus Administration 
The whole blood concentration time courses for the four intravenous 
bolus doses administered to the dog are shown in Fig. 1. This semilogarith- 
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Fig. 1. Penicillamind whole blood concentration vs. time for four i.v. 
bolus doses of penicilia~ine in a female mongrel dog. Squares, 
14.3 mg/kg; circles, 10.7 mg/kg; triangles, 7.1 mg/kg; stars, 3.6 mg/kg. 
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D-penicillamine in the female mongrel dog. The terminal log-linear phases 
for the four different doses are not parallel as is expected for a linear 
system, but the slope of the terminal log-linear phases are decreasing with 
increased dosage. This change in the slope with the dose corresponds to 
an increase in the half-life and a decrease in the clearance of penicillamine 
with an increase in the penicillamine dose. 
The whole blood concentration data of these four experiments were 
stripped using the digital computer program CSTRIP (24) and were found 
to fit a triexponential function significantly better than a biexponential. 
Using the preliminary estimates for the triexponential fits from CSTRIP, 
the i.v. bolus dog data were fitted by the method of least squares to a 
triexponential equation using the digital computer program N O N L I N  (25). 
Because of the excellent fits obtained with NONLIN,  (R 2 and Corr > 
0.999), the triexponential functions were used to calculate the pharma- 
cokinetic parameters shown in Table I. The results presented in this table 
also demonstrate the dose dependent pharmacokinetics of penicillamine 
in this female mongrel dog. As the dose was increased, there was a significant 
decrease in the total body clearance of penicillamine and an increase in 
the ha[f-]ife. Also shown in Table I is the percentage of the dose of 
penicillamine that was excreted unchanged in the urine. The urinary data 
also demonstrated 2, .dose dependency as the percentage of the dose excreted 
in the urine was increased as the dose increased. 
The asymptotic values of ,*he cumulative amount excreted for each 
dose were divided into the respecti*~ cumulative amounts at each time 
Table I. Pharmacokinetic Parameters of Penicillamine Determ~R5 d from Four i.v. Bolus 
Doses in a Female Mongrel Dog 
Area under Total Elimination AMOunt in 
Dose curve a clearance b Half-life c rate constant a urine ~ 
(mg/kg) (~g * min/ml) (ml/min) (hr) (hr -1) (% dose) 
3.6 278 326 0.69 1.00 14.6 
7.1 690 268 0.97 0.716 17.6 
10.7 1160 211 1.4 0.494 23.5 
14.3 1600 196 1.2 0.576 26.3 
aThe area under the whole blood concentration curve from time zero to infinity is calculated 
by integration of the NONLIN polyexponential function fit to the observed whole blood 
concentration data. 
bThe total body clearance calculated from the ratio of the dose (~g) over the whole blood 
AUC (/xg * min/ml). 
CThe half-life determined from the smallest rate constant of the NONLIN fit of the observed 
whole blood concentration data. 
dThe elimination rate constant from the NONLIN fit. 
~The cumulative amount of penicillamine found in the urine extrapolated to infinity and 
expressed as a percentage of the administered dose. 
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point, and these ratios are plotted against time. As shown in Fig. 2, the 
curves are not superimposed. The order of the curves for these ratios are 
reversed with respect to the dose such that the largest dose gives the 
smallest ratios. These results confirm that the urinary excretion data for 
penicillamine in this dog are dose dependent.  
As shown in Fig. 3, the urinary excretion rate of penicillamine was 
not directly proportional to the concentration of penicillamine in the whole 
8 


















Fig. 2. Ratios of the amount of penicillamine excreted in the urine 
over the amount excreted to infinity vs. time for the four i.v. bolus 
doses of penicillamine in a female mongrel dog. Squares, 14.3 mg/kg; 
circles, 10.7 mg/kg; triangles, 7.1 mg/kg; stars, 3.6 mg/kg. 
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Fig, 3. Penicillamine urinary excretion rate in a female mongrel dog 
vs. the average whole blood penicillamine concentration at the mid- 
point of the urine collection interval for the four i.v. bolus doses of 
penicillamine. Squares, 14.3 mg/kg; circles, 10.7 mg/kg; triangles, 
7.1 mg/kg; stars, 3.6 mg/kg. 
blood. These results demonstrate that the "apparent" renal clearance of 
penicillamine was increased by the higher blood levels of penicillamine. 
These concentration dependent changes observed in the renal clearance 
of penicillamine for each i.v. bolus dose may be the result of nonlinear 
plasma protein binding for penicillamine. 
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Oral Administration 
The whole blood levels of penicillamine resulting from the administra- 
tion of four single oral doses of penicillamine are shown in Fig. 4. Two of 
the doses, both administered as oral solutions, gave a single peak blood 
level curve, the typical profile for oral administration. However, the other 
two doses, administered as an oral solution and as a capsule solid dosage 
form, displayed atypical double blood level patterns. The blood level profile 
resulting from the administration of the capsule dosage form is highly 
x 
~ o") - 
co- 
r-,-- 
u ~ -  
u ~ -  
. 9  
8 xtn 
o a -  
<F r--- 
F-- ~ o -  
z 





Ixl ~ _ _  
~ t o -  
a_ 
~I I i I i i 
: "  O.O0 6 . 0 0  120.00 ISO.~ 240.00 300.00 360.00 
TIME ( r I I N U T E S )  
Fig. 4. Penicillamine whole blood concentration vs. time for four oral 
doses of penicillamine in a female mongrel dog. Squares, 14.3 mg/kg 
(solution); circles, 10.7 mg/kg (solution); triangles, 10.7 mg/kg (sol- 
ution); stars, 9.9 mg/kg (capsules). 
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i r regular ,  showing  a m a r k e d  d o u b l e  p e a k ,  a s ignif icant  shift  in the  re la t ive  
t ime  course ,  and  a s ignif icant  r educ t i on  in the  b ioava i l ab i l i t y  of the  capsu le  
dosage  fo rm re la t ive  to the  doses  a d m i n i s t e r e d  as o ra l  so lu t ions .  
C o m p a r i s o n s  of  the  a r ea  u n d e r  the  curves  ( A U C )  for  the  ora l  doses  
and  i.v. bolus  doses  were  d o n e  in o r d e r  to d e t e r m i n e  the  b ioava i lab i l i ty .  
The  A U C  da t a  and  ca lcu la t ed  b ioava i l ab i l i t y  fac tor  a re  shown in T a b l e  II .  
The  b ioava i l ab i l i t y  fac tor  r e p o r t e d  for  the  o ra l  so lu t ions  is h igher  than  tha t  
r e p o r t e d  p rev ious ly  (13), bu t  the  b ioava i l ab i l i t y  fac tor  r e p o r t e d  for  the  
sol id  dosage  fo rm is a p p r o x i m a t e l y  the  s ame  as the  p rev ious  r epor t .  
I n t r a v e n o u s  I n f u s i o n s  
T h e  s t eady  s ta te  who le  b lood ,  p lasma ,  and  p a c k e d  cell levels  of  pen ic i l -  
l amine  ach ieved  dur ing  six cons tan t  ra te  pen ic i l l amine  infusions  a re  l is ted 
in T a b l e  III .  T h e  s t eady  s ta te  p l a sma  concen t r a t i on  is p l o t t e d  vs. infus ion  
ra te  in Fig.  5. The  to ta l  b o d y  c lea rance  of pen ic i l l amine  was ca lcu la t ed  for  
each  infusion using the  s t eady  s ta te  p l a s m a  and  whole  b l o o d  concen t ra t ions ,  
the  respec t ive  infusion rates ,  and  Eq.  (1): 
k0 
CL = - -  (1) 
G~ 
where  CL is the  to ta l  b o d y  c learance ,  ko is the  infus ion ra te ,  and  C~ is the  
b l o o d  c o m p o n e n t  s t e ady  s ta te  concen t ra t ion .  The  ca lcu la t ed  p l a s m a  and  
whole  b l o o d  to ta l  b o d y  c learances  for  the  six infusions  are  shown in 
T a b l e  III .  
Table II. Calculation of FF *a from the Oral and I.V. Dog Experiments for Penicillamine 
Oral Oral i.v. 
Dose b dose dosage AUCp~ ~176 dose AUC~ ~176 
(mg/kg) (rag) form (t~g/ml/min) c (mg) (tzg/ml/min) ~ FF* 
14.3 370 soln. 1800 315 1600 0.96 
10.7 287 soln. 1110 245 1160 0.82 
10.7 300 soln. 921 245 1160 0.65 
9.92 250 caps. 608 245 d 1160 0.51 
aFF*, the bioavailability factor, is the fraction of the dose that ultimately reaches the 
circulation. It is the factor used to account for losses due to incomplete absorption and or 
first pass effects where: 
0--o~ 
a U C p o  x D  iv 
FF* = " " 
AUC~ ~176 • Dpo 
bThe dose was administered as a solution of penicillamine (50 mg/ml; see text) or as 125 mg 
capsules. 
CThe AUC is the area under the whole blood concentration-time curve from zero to infinity. 
dThis dose was actually administered as a 10.7 mg/kg dose i.v. 
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Table III. Steady State Blood Levels of Penicillamine Achieved During Four Hour 
Constant Rate Intravenous Infusions of Penicillamine in a Female Mongrel Dog 
Steady state levels a Clearance b 
(tzg/ml) (ml/min) 
Infusion 
rate Whole Packed Whole 
(/~g/min) blood Plasma cells blood Plasma 
209 0.667 0.821 0.294 313 255 
(0.022) c (0.041) (0.049) 
412 1.70 2.01 0.814 243 205 
(0.040) (0.071) (0.008) 
824 3.93 5.26 2.29 210 157 
(0.063) (0.26) (0.21) 
1270 6.53 9.74 3.85 194 130 
(0.26) (0.36) (0.26) 
1680 11.2 15.1 6.28 150 111 
(0.30) (0.76) (0.75) 
2130 14.5 19.4 8.64 147 110 
(0.80) (0.21) (0.22) 
aThe average of three observations made during the fourth hour of the intravenous 
infusion. 
bThe total body clearance calculated from the ratio of the infusion rate over the steady 
state concentration. 
CThe standard deviations of the observed data points. 
F r o m  a d e t e r m i n a t i o n  of the  a m o u n t  of pen ic i l l amine  exc re t ed  in the  
ur ine  over  an accura te ly  t i m e d  in te rva l  dur ing  the  final hour  of each  infusion,  
the  u r ina ry  excre t ion  ra te  of pen ic i l l amine  at s t e ady  s ta te  was d e t e r m i n e d .  
T h e  o b s e r v e d  ur ine  exc re t ion  ra te  was d iv ided  by  the  respec t ive  s t eady  
s ta te  whole  b l o o d  and  p l a s m a  concen t r a t ions  to  ca lcula te  a whole  b l o o d  
or  p l a s m a  rena l  c l ea rance  of pen ic i l l amine ,  as shown in Eq.  (2): 
dAe/ dt 
CLr = - -  (2) 
cs, 
where  CL, is the  rena l  c lea rance ,  and  dAe/dt is the  u r ina ry  excre t ion  ra te  
at  s t eady  state .  A t  s t e ady  s ta te ,  the  ra te  of inpu t  mus t  equa l  the  ra te  of 
e l imina t ion  of the  drug.  The re fo re ,  the  r e l a t ionsh ip  exp res sed  in Eq.  (3) 
exists:  
ko = dAe/ dt + dAm/ dt (3) 
where  dAm/dt is the  n o n r e n a l  e l imina t ion  ra te  at s t eady  s ta te .  Because  
the  infus ion ra tes  of  pen ic i l l amine  t h a t w e r e  used  are  accura te ly  known,  
and  the  u r ina ry  excre t ion  ra tes  were  d i rec t ly  m e a s u r e d ,  the  non rena l  
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Fig. 5. Steady state penieillamine concentrations of plasma, whole 
blood, and packed cells vs. the penieillamine intravenous infusion 
rate in a female mongrel dog. Triangles, plasma levels; circles, 
whole blood levels; squares, packed cell levels. 
elimination rates of penicitlamine in the dog can be calculated by solving 
Eq. (3) for dAm/dr. These rates are plotted vs. steady state concentration 
in Fig. 6. 
The observed urine elimination rates for five of the six intravenous 
infusions and the calculated renal and nonrenal  clearances of penicillamine 
are listed in Table IV. The urinary elimination rate data for the 1270/~g/ml 
infusion were omit ted because of an error that occurred during the collec- 
tion of the urine specimen. 
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Fig, 6. The nonrenal elimination rate of penicillamine vs. the steady 
state concentrations of penicillamine in plasma and whole blood of 
a female mongrel dog. Circles, whole blood; triangles, plasma. 
DISCUSSION 
The pharmacokinetic parameters determined for D-penicillamine in 
the female mongrel dog exhibited nonlinear relationships relative to the 
doses. For the i.v. bolus studies, as the dose was increased over a fivefold 
range, there was a reduction in the total body clearance and an increase 
in the estimated half-life. The doses of penicillamine were administered to 
the dog on a mg/kg basis such that the doses were equivalent to administer- 
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Table IV. Urinary Excretion Rates ~ and Renal and Nonrenal Clearances of Penicillamine 
after the Attainment of Steady State During Four Hour Constant Intravenous Infusions in 
a Female Mongrel Dog 
Renal clearance c Nonrenal clearance d 
Urine (ml/min) (ml/min) 
Infusion Excretion b 
rate rate Whole Whole 
(/zg/min) (p.g/min) blood Plasma blood Plasma 
209 10.9 16.3 13.3 297 242 
412 57.8 34.0 28.8 209 176 
824 234 59.5 44.4 150 113 
1270 e . . . .  
1680 698 62.3 46.2 87.7 64.8 
2130 1090 74.9 56.0 72.1 54.0 
~The urine was collected over the last hour of the intravenous infusion when the blood levels 
of penicillamine were at steady state. 
bThe urinary excretion rate is calculated from the amount of unchanged penicillamine excreted 
in the urine during the last hour of the intravenous infusion divided by the length of the 
urine collection period. 
CThe renal clearance was calculated by dividing urinary excretion rate by the steady state blood 
level. 
dThe nonrenal clearance was calculated from the difference between the total body clearance 
(see Table II) and the calculated renal clearance for a given infusion rate. 
eThese data were omitted due to an error in the collection of the urine specimen. 
ing 250,  500,  750,  and  1000 mg of  D-pen ic i l l amine  to a 70 kg man ,  the  
dosage  r ange  used  clinically.  
A s  in the  case of  the  i.v. bolus  resul ts ,  the  infus ion  d a t a  we re  non l inea r ,  
also showing  a dec rea se  in the  to ta l  b o d y  c l ea rance  as the  infus ion r a t e  
increased .  F o r  the  infus ion d a t a  p r e s e n t e d  in T a b l e  I I I ,  the  la rges t  change  
in the  to ta l  b o d y  c l ea rance  of pen ic i l l amine  occu r r ed  at  the  lowes t  two 
infus ion  rates .  T h e  o b s e r v e d  dec rease  in the  c l ea rance  b e c a m e  less the  
m o r e  the  infus ion r a t e  was inc reased .  A s imi lar  conc lus ion  is d r a w n  f rom 
T a b l e  I for  the  i.v. bo lus  da ta .  In  these  da ta ,  the  la rges t  change  in the  
c l ea rance  o c c u r r e d  b e t w e e n  the  two lowes t  doses  and  the  smal les t  change  
b e t w e e n  the  h ighes t  doses .  These  resul ts  suggest  tha t  t h e r e  a re  pa ra l l e l  
non l inea r  and  l inear  e l imina t ion  p rocesses  for  pen ic i l l amine  in this f ema le  
m o n g r e l  dog.  A s  the  dosage  ra te  was inc reased ,  the  non l inea r  e l imina t ion  
p rocess  b e c a m e  sa tu ra t ed ,  and  the  overa l l  e l imina t ion  kinet ics  of pen ic i l -  
famine  a p p r o a c h e d  l inear i ty .  
T h e  r e l a t ionsh ip  b e t w e e n  the  infus ion ra te  and  the  s t eady  s ta te  con-  
cen t r a t ion  can t h e r e f o r e  be  d e s c r i b e d  by  Eq.  (4), which  consists  of  l inea r  
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and nonlinear components: 
ko=C~,[e(1). ~ P(2) ] 
e(3-~ C'~3 
(4) 
where P(1) has units of clearance, volume/time, P(2) has units of 
mass/time, and P(3) has units of mass/volume. However, Eq. (4) is written 
expressing the infusion rate as a function of the steady state concentration. 
An explicit solution for the steady state concentration as a function of the 
infusion rate does not exist, but Eq. (4) can be rearranged into a quadratic 
function as shown in Eq. (5): 
P(1),(C~)2+(p(1),P(3)+P(2)-ko),C~-ko,P(3)=O (5) 
Therefore, the steady state concentration can be expressed as the positive 
quadratic root of Eq. (5), as shown in Eq. (6): 
-b + SQR (b 2 - 4ac) 
Css - (6) 
2a 
where a = P(1), b =P(1) * P(3)+P(2)-ko, and c = -k0 * P(3). 
Initial estimates of the parameters P(1), P(2), and P(3) were obtained 
graphically. A linear regression of the data for the three highest infusion 
rates gave the initial estimates for P(1), the slope from the regression, and 
P(2), the intercept from the linear regression. An initial estimate of P(3) 
was obtained by solving Eq. (4) for P(3) and using the observed infusion 
rate steady state concentration data and the initial estimates of the other 
parameters to give an average initial estimate of P(2). 
The plasma and whole blood concentration data were fitted to Eq. 
(5), using the digital computer program NONLIN (25) and the initial 
estimates of the parameters P(1), P(2), and P(3). Summaries of the results 
of the NONLIN fits for the plasma and whole blood data are shown in 
Table V. 
The exact interpretation of these parameters, however, is not clear, 
as the parameters of Eq. (4) are pooled parameters resulting from the 
overall elimination process for penicillamine in this female mongrel dog. 
Both the renal and nonrenal components of clearance were observed to 
be nonlinear, as shown in Table IV. Thus the linear and nonlinear com- 
ponents of penicillamine's elimination as theorized by Eq. (4) cannot be 
accurately ascribed to specific physiological functions by a simple assess- 
ment of the observed data. 
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Table V. Summary of the Results of the NONLIN Fit of the Intravenous Infusion Rates of 
Penicillamine and the Steady State Whole Blood and Plasma Concentration Levels 
Parameters a 
Steady state Number of P(1) P(2) P(3) 
level of observations (ml/min) (rag/rain) (tzg/ml) R 2 b 
Plasma 18 82.6 0.565 2.49 0.999 
(4.2) (0.093) (0.71) 
Whole blood 15 110 0.594 2.47 0.998 
(7.3) (0.132) (0.75) 
~The parameters of Eq. (4) used to express the relationship between the infusion rate and 
the steady state concentration in plasma or whole blood. 
bThe coefficient of determination for the NONLIN fits. 
The renal excretion rates observed in both the i.v. bolus and the 
infusion studies were nonlinear; the observed nonlinearity may be the result 
of nonlinear penicillamine plasma protein binding, as has been demon- 
strated for other compounds (26,27). However, due to rapid degradation 
of penicillamine in the presence of biological media such as albumin 
solutions or plasma (19), the protein binding of penicillamine cannot be 
easily and accurately determined using conventional methods. 
The relationship of the nonrenal elimination rate versus the steady 
state concentration is shown in Fig. 6. From these data it is apparent that 
the nonrenal elimination kinetics of penicillamine in this female mongrel 
dog can be described by Michaelis-Menten kinetics. As the steady state 
or infusion rate was increased, there was a less than proportional increase 
in the nonrenal elimination rate. As the larger infusion rates were employed, 
the nonrenal elimination process approached a saturation level, 
In conclusion, the data presented for the i.v. bolus and infusion studies 
of penicillamine in this female mongrel dog are consistent with a model 
for penicillamine involving metabolism occurring according to one probably 
pooled Michaelis-Menten kinetic process and renal excretion probably 
occurring according to nonlinear saturable protein binding. More studies 
are necessary to accurately characterize the pharmacokinetics of penicil- 
lamine following oral administration in the female mongrel dog. But the 
results presented in this paper give an indication of some of the general 
characteristics of penicillamine upon oral administration. 
The presence of a double peak following oral administration of penicil- 
lamine in the female mongrel dog presents an unusual pharmacokinetic 
profile for the oral administration of a drug. However, similar double peaks 
have also been observed following oral administration of penicillamine in 
man (29) as well as for other drugs (30-32). 
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